로딩 중…
StockDiggingStockDigging

Bristol-Myers Squibb Company

BMY· NYSE
$65.46+0.23%
2026-08-03

Financials

Valuation Metrics

Bristol-Myers Squibb Company's Market Cap is $133.67B. At end of 2025 it was $108.81B. Ranked #121 of 3,112 in US market (top 4%), #80 of 1,667 on NYSE (top 5%), #11 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 4%) by Market Cap.

Investment Metrics(as of 2026-08-03)

MetricValue
Size
Market Cap$133.67B
Revenue$49.19B
Net Income$9.28B
Total Assets$87.63B
Net Assets$22.32B
Employees32,500
Value
P/E14.40x
P/B5.99x
PEG0.09x
P/S2.72x
EV/EBITDA10.08x
FCF Yield8.56%
Profitability
ROE41.59%
ROA10.59%
Op. Margin28.27%
Revenue Growth5.74%
Earnings Growth153.21%
Financial Health
Debt Ratio292.64%
Total Debt$43.12B
FCF$11.44B
Cash$8.72B
Current Ratio1.53x
Net Debt/EBITDA2.06x
Dividend
Div. Yield3.81%
Div. Growth3.03%
Performance
1Y Return51.81%
1M Return12.61%
From 52W High-3.88%
1Y MDD-13.68%
Trading
Volume24,636,623 shares
Trading Value$1.62B
Per Share
EPS$3.46
BPS$9.05

Company Info

CEO Dr. Christopher S. Boerner Ph.D.
Employees 32,500
HQ Princeton, United States

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.